Top Trends Transforming the Roxadustat Market Landscape in 2025: Roxadustat Reimbursement Under Ireland's High Tech Drugs Scheme Accelerates Market Growth

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Roxadustat Industry Market Size Be by 2025?
There has been a robust growth in the roxadustat market in the past few years. The market is predicted to expand from a size of $6.44 billion in 2024 to $6.86 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.5%. The factors contributing to this consistent growth during the historical phase include regulatory authorizations in key markets, compelling results from clinical trials, the growing incidence of chronic kidney disease, heightened awareness about anemia management, and governmental backing for anemia therapies.

What's the Long-Term Growth Forecast for the Roxadustat Market Size Through 2029?
In the coming years, the roxadustat market is projected to experience robust growth, reaching a value of $8.95 billion by 2029, increasing at a compound annual growth rate (CAGR) of 6.9%. This growth over the forecast period may be driven by the ongoing investigations for new applications, growing healthcare spending, the rising demand for non-invasive anemia treatments, broadening insurance coverages, and an increasing aging population. Key trends for the forecast period include a move towards oral anemia remedies, intensifying competition from alternative treatment methods, the expansion of licensing deals, increasing investments in hypoxia-inducible factor research, and an emphasis on patient-centric treatment methods.

View the full report here:
https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report

What Are the Key Growth Drivers Fueling the Roxadustat Market Expansion?
The escalating prevalence of individuals suffering from chronic kidney disease (CKD) is anticipated to stimulate the expansion of the Roxadustat market in the future. Chronic kidney disease, a protracted condition characterized by a steady decrease in kidney functionality, poses the threat of kidney failure if not appropriately addressed. The global increase in CKD cases can be attributed to factors like ageing demographic, growing rate of diabetes, hypertension and unhealthy living habits. Roxadustat assists in the regulation of CKD by promoting the production of erythropoietin, thereby enhancing red blood cell production and alleviating anemia often connected with this ailment which ultimately betters kidney function and living standards for those affected. For example, a study by the Australian Institute of Health and Welfare (AIHW), a government institution in Australia, showed a slight annual surge in the mortality rates from chronic kidney disease, recording increases of 4.2% in 2021 and 6.2% in 2022. Consequently, this rising prevalence of people suffering from chronic kidney disease (CKD) is intensifying the expansion of the Roxadustat market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Roxadustat Market?
Prominent corporations engaged in the Roxadustat market are pursuing reimbursement under the high-tech drugs scheme. This strategy aims to remove financial hurdles to patient accessibility, propel market uptake, and exhibit the cost-effectiveness of their groundbreaking treatments. The high-tech drugs program is predominantly overseen by the Irish government and reimburses the provision of costly, highly bespoke medications usually prescribed in hospital contexts. For example, in September 2022, Astellas Pharma Company Ltd., a US-located pharmaceutical firm disclosed that its product, EVRENZO (Roxadustat), has been approved for reimbursement under the High-Tech Drugs Scheme in Ireland. Roxadustat is the inaugural drug from the novel class of oral hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors licensed and reimbursed in Ireland. The outcome illustrated that Roxadustat was successful in attaining and retaining target hemoglobin rates (10-12g/dL) in patients suffering from symptomatic anemia of CKD, no matter their dialysis status and previous ESA treatment.

How Is the Roxadustat Market Segmented?
The roxadustat market covered in this report is segmented -

1) By Type: 20mg, 50mg
2) By Product Formulation: Oral Tablets
3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers
4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp

Which Companies Are Leading the Charge in Roxadustat Market Innovation?
Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

Which Regions Are Leading the Global Roxadustat Market in Revenue?
North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21280

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.